Diseases that the medical community acknowledges lumbrokinase has primarily effective against at :

• Coronary artery disease

t-PA and PAI are a pair of important biological regulators synthesized and secreted by vascular endothelial cells. They play an important role in regulating the fibrinolytic system. Specifically, t-PA can selectively bind to fibrin in thrombus to produce thrombolytic effect. PAI, on the other hand, is a fast inhibitor that irreversibly binds to t-PA and urokinase, thereby inactivating them. PAI can also inhibit the function of urokinase, which is essential for regulating the fibrinolytic system. In patients with coronary heart disease, increased PAI activity can lead to hypofibrinolysis by inhibiting t-PA activity. Urokinase mainly activates plasminogen in plasma, converts it into plasmin with thrombolytic activity, and finally degrades fibrinogen and fibrin clot to melt thrombus. In addition, lumbrokinase can melt fibrin directly. The study showed that after 12 hours of treatment, the activity of plasma t-PA in the AMI group increased significantly, and the difference was still significant on the third day after treatment. On the 7th day, the activity gradually returned to the original level. After 5 days of lumbrokinase treatment, the function of the fibrinolytic system was significantly improved. Therefore, urokinase thrombolysis and oral lumbrokinase can significantly improve the fibrinolytic system and reduce the risk of re-infarction after thrombolysis.

• Cerebral infarction

Cerebral infarction is the most common cerebrovascular disease, accounting for about 50% to 60% of all cerebrovascular diseases. Stroke has become the leading cause of death among older adults in many countries. Ischemic stroke accounts for 60% to 80% of the total incidence of stroke, and the disability rate is high. In the acute stage of cerebral infarction, measures such as controlling cerebral edema, increasing cerebral blood flow and cerebral tissue oxygen saturation are extremely beneficial to patients. According to clinical observations, 665 patients with cerebral infarction took lumbrokinase capsules orally for 15-28 days, the effective rate was 60.94%-73.66%, and the total effective rate was 88.0%-98.88%. 98.6% of patients had a significant reduction in embolism volume, and the average embolism volume reduction rate was 74.1%. After taking the medicine for 3 to 5 days, the mouth and eyes were deviated, and the improvement rate of limb numbness reached 79.85%. After treatment, the improvement rate of dizziness and headache was 95.95%. The improvement rate of tongue stiffness was 94.7%, the improvement rate of mouth and eye deviation was 91.3%, the improvement rate of hemiplegia was 92.3%, the improvement rate of limb numbness was 92.9%, and the improvement rate of hand and foot urgency was 85.7%. Clinical studies have confirmed that lumbrokinase has a unique affinity with fibrin, does not affect the normal blood coagulation system function of the body, and can significantly reduce the scope of the ischemic penumbra. The use of lumbrokinase in the treatment of cerebral infarction has a significant effect on the recovery of paralyzed limbs, can effectively improve the clinical symptoms and signs of patients, and reduce the disability rate. The sequelae of this drug are mild, and the marked rate and effective rate are significantly better than anti-abdominal snake thrombosis and Xueshuan Xinmaining. The recurrence rate was significantly lower than that of ordinary aspirin therapy and ticlopidine hydrochloride, and the side effects of other drugs were mild. It is an ideal oral antithrombotic drug similar to t-PA for the prevention and treatment of cerebral infarction.

• Diabetes

Plasma GMP140 is a product released by activation of platelets or endothelial cells. Studies have shown that the determination of the content of GMP140 in plasma can reflect the degree of platelet activation and the tendency of thrombosis in vivo. On the other hand, TXB2, a metabolic end product of XA2, strongly promotes platelet aggregation and vasoconstriction. Studies have shown that the levels of plasma GMP140 and TXB2 in diabetic patients are significantly increased, indicating that their platelets are in an activated state. Enhanced platelet adhesion and aggregation is one of the reasons why diabetic patients are prone to early high incidence of arteriosclerosis and complex microvascular diseases. Lumbrokinase is a group of acidic proteins extracted from artificially reared Eisensis. Plasma TXB2 levels were significantly decreased in diabetic patients after oral administration of lumbrokinase for two weeks, and there was no significant difference compared with the control group. This indicates that lumbrokinase has a significant inhibitory effect on platelet adhesion and aggregation. The level of plasma GMP140 also decreased significantly after treatment, indicating that lumbrokinase can inhibit platelet activation in diabetic patients to a certain extent.

•Neprotic syndrome

Lumbrokinase is a group of proteolytic enzymes extracted from special earthworms. In 1984, the preliminary research results of Tsinghua University and other institutions showed that lumbrokinase has the functions of thrombolysis, anticoagulation and defibrillation. At present, its mechanism of action has been confirmed. First, it acts as a plasminogen activator (similar to t-PA); second, it binds to fibrin, causing it to degrade rapidly. Lumbrokinase has direct and indirect thrombolytic functions. The coagulation activity of the internal coagulation system is often enhanced in patients with nephrotic syndrome. Increased fibrinogen promotes blood coagulation and microthrombosis in glomerular capillaries. Most NS patients are in a hypercoagulable state and have a tendency to form thrombus. The research results of Hou Ming et al. A study by the Affiliated Hospital of Shandong Medical University showed that the reduction of plasminase activity (mainly t-PA) and the enhancement of fibrinolytic inhibitory activity (mainly a2-PA) are important reasons for the formation and progression of chronic blood hypercoagulability. Glomerular disease. The experimental examination of this group showed that fibrinogen and blood viscosity indexes were significantly increased, which was similar to the reports of some domestic scholars. It is speculated that the use of lumbrokinase in the treatment of PNS is to supplement or increase the content of t-PA in the blood, rebalance the imbalance of activators and inhibitors in the blood fibrinolytic system in NS, and exert anticoagulant and anticoagulant effects. Thrombolysis improves glomerular microcirculation, reduces urinary protein, and improves renal function. In 1983, Hisashi Mihara of Miyazaki University in Japan used earthworm extract to treat thousands of cases of thromboembolic diseases clinically, with an effective rate of over 80%. In 1993, Zhu Changlian and others. Nine cases of primary glomerular diseases were reported. After oral administration of lumbrokinase extract, the 24-hour urinary protein quantity was significantly lower than that before treatment. Two cases of renal insufficiency were significantly improved after treatment with lumbrokinase. The results of the treatment are encouraging. The total effective rate of 20 cases of PNS patients in this group after treatment was 95%, which was significantly higher than 65% in the control group, P<0.05, the difference was statistically significant. The difference in curative effect between type I and type II may be related to the longer course of disease, the degree of renal damage, and the different pathological types. For many reasons, the research on the relationship between pathological classification and curative effect needs to be further explored.

•Pulmonale

Clinical studies of lumbrokinase in the treatment of cor pulmonale have confirmed that the hemorrheology indicators of patients are significantly changed, clinical symptoms are improved, and the total effective rate of treatment is 88.4%. The patient's nailfold microcirculation examination showed that red blood cells aggregated before treatment, and the blood color was dark red. However, after treatment, the symptoms improved, the oxygen content in the patient's body increased, and the symptoms of chest tightness, shortness of breath, and cyanosis were alleviated. No adverse reaction is reported, and it is a safe and effective antithrombotic drug for the treatment of pulmonary heart disease.

•Deep vein thrombosis of lower extremities

Deep vein thrombosis of the lower extremities can occur acutely within 3 to 7 days, and become chronic after 7 days. Thrombolytic therapy, such as urokinase, has been found to be effective in acute cases but is generally not effective in chronic cases. Chronic deep vein thrombosis is relatively common clinically, and there is no ideal treatment method at present. However, oral administration of lumbrokinase 2 tids for 21 days has a total effective rate of 79.99% for lower extremity deep vein thrombosis, and 28.57% of the cases showed significant improvement. The total effective rate was equivalent to subcutaneous injection of small molecule heparin (82.20%). Therefore, lumbrokinase is considered to be an effective option.